Orion Biotech Opportunities Corp. Units
ORIAU
ORIAU was delisted on the 25th of April, 2023.
44 hedge funds and large institutions have $148M invested in Orion Biotech Opportunities Corp. Units in 2021 Q2 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP
JNE Partners
London,
United Kingdom
|
+$15.1M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
+$10.1M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$8.06M |
| 4 |
SCC
Spring Creek Capital
Wichita,
Kansas
|
+$8.06M |
| 5 |
LA
Linden Advisors
New York
|
+$7.05M |
Top Sellers
ORIAU Hedge Fund Activity: Q2 2021 in Review
44 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Units (ORIAU) for Q2 2021, worth a combined $148M.
Buyers outnumbered sellers: 44 funds opened new ORIAU positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was JNE Partners, opening a new position worth an estimated $15.1M.
- 44 institutional investors held Orion Biotech Opportunities Corp. Units (ORIAU) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $148M of Orion Biotech Opportunities Corp. Units stock for Q2 2021.
- 44 funds opened new Orion Biotech Opportunities Corp. Units positions in Q2 2021 and 0 closed out, a net change of +44 holders.
- The largest Orion Biotech Opportunities Corp. Units buyer in Q2 2021 was JNE Partners, an estimated $15.1M added.
Based on aggregated 13F filings for Q2 2021.